Riskpilot← Back to searchSign inGet full accessMACURE PHARMA ApS
APSActiveCVR 35234748Hejrevej 39Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201325 employees
Revenue 2024
DKK 39,1M
+62% vs 2023
EBITDA margin
61.5%
+87% vs 2023
Equity ratio
7.4%
Financial strength
Net profit 2024
DKK 8,5M
-3% vs 2023
| Revenue | DKK 39,1M | +62% |
| EBITDA | DKK 24M | +87% |
| Net profit | DKK 8,5M | -3% |
| Total assets | DKK 202,5M | +19% |
| Equity | DKK 15M | +6% |
| Employees | 25 | — |
Legal name
MACURE PHARMA ApS
CVR number
35234748
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. maj 2013
Share capital
DKK 80.000
Employees
25 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive handelsvirksomhed inden for den farmaceutiske industri.
Address
Hejrevej 39
Phone
+4570204107
Email
info@macurepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -171 | 214 | 680 | 13.296 | 14.377 | 10.257 | 16.325 | 15.149 | 24.982 | 37.527 | 24.159 | 39.051 |
| Staff expenses | -0 | -0 | -23 | -1.478 | -2.822 | -3.070 | -4.158 | -8.099 | -18.272 | -15.700 | -11.354 | -15.044 |
| EBITDA | -171 | 214 | 658 | 11.818 | 11.555 | 7.187 | 12.167 | 7.050 | 6.710 | 21.827 | 12.805 | 24.007 |
| Depreciation & amort. | -0 | -56 | -68 | -74 | -87 | -220 | -146 | -137 | -153 | -138 | -1.253 | -438 |
| EBIT | -171 | 158 | 589 | 11.743 | 11.468 | 6.967 | 12.021 | 6.913 | 6.557 | 21.689 | 11.552 | 23.569 |
| Net financials | -2 | -68 | -48 | -69 | -31 | -100 | -205 | -153 | -73 | 1.286 | -186 | -12.660 |
| Profit before tax | -172 | 90 | 541 | 11.675 | 11.437 | 6.867 | 11.816 | 6.760 | 6.484 | 22.975 | 11.366 | 10.909 |
| Tax | -43 | 23 | 134 | 2.579 | 2.523 | 1.531 | 2.628 | 1.502 | 1.436 | 5.081 | 2.576 | 2.414 |
| Net profit | -130 | 66 | 407 | 9.095 | 8.913 | 5.335 | 9.188 | 5.258 | 5.048 | 17.895 | 8.790 | 8.495 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 265 | 3.182 | 11.392 | 22.454 | 25.360 | 33.942 | 44.046 | 57.552 | 100.485 | 114.206 | 170.273 | 202.510 |
| Equity | -50 | 417 | 823 | 5.458 | 11.971 | 10.507 | 14.194 | 10.452 | 10.500 | 23.394 | 14.185 | 14.980 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 133 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 314 | 2.759 | 10.546 | 16.950 | 13.388 | 23.378 | 29.697 | 47.100 | 89.985 | 90.812 | 156.089 | 187.530 |
| Total debt | 314 | 2.759 | 10.546 | 16.950 | 13.388 | 23.378 | 29.831 | 47.100 | 89.985 | 90.812 | 156.089 | 187.530 |
EBITDA margin
61.5%
This company
15.8%
Market median
+289% vs market
20132024
Equity ratio
7.4%
This company
38.2%
Market median
-81% vs market
20132024
Return on equity
56.7%
This company
18.4%
Market median
+208% vs market
20132024
Net profit margin
21.8%
This company
8.1%
Market median
+169% vs market
20132024
Asset turnover
0.19×
This company
1.12×
Market median
-83% vs market
20132024
Debt / equity
12.52×
This company
0.62×
Market median
-1919% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-05-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LM Management | Management | 2016 | — | — |
SS Management | Management | 2013 | — | — |
MR Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nest Egg ApS | Company | 100.0% | 100.0% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
POMALA HOLDING ApS
MACURE PHARMA ApS Board members of MACURE PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Mark Poulsen | Management | 0 companies |
| Simon Søberg Jørgensen | Management | 0 companies |
| Mads Renlef Henningsen | Chief Executive Officer | 0 companies |